Results 21 to 30 of about 10,088 (191)

Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS

open access: yesHepatology, EarlyView., 2022
The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck   +14 more
wiley   +1 more source

Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice

open access: yesBMC Microbiology, 2023
Background Rifaximin has been increasingly applied in irritable bowel syndrome (IBS) treatment. Whether there were differences in the effects of rifaximin on microbiota from different intestinal segments, especially the small intestine where rifaximin ...
Shengyan Zhang   +5 more
doaj   +1 more source

High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy

open access: yesHepatology Communications, 2023
Background and Aims:. Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low.
Elizabeth S. Aby   +4 more
doaj   +1 more source

Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. [PDF]

open access: yesPLoS ONE, 2013
Rifaximin is a semi-synthetic rifamycin derivative that is used to treat different conditions including bacterial diarrhea and hepatic encephalopathy.
Caroline Schrodt   +4 more
doaj   +1 more source

The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials [PDF]

open access: yesMicrobiota in Health and Disease, 2020
Objective: Recent randomized control trials (RCTs), have demonstrated the beneficial therapeutic effects of rifaximin for the treatment of the irritable bowel syndrome (IBS).
T. Rokkas   +8 more
doaj   +1 more source

Effect of rifaximin in the prevention of acute kidney injury and hepatorenal syndrome type II in Egyptian cirrhotic patients [PDF]

open access: yesZagazig University Medical Journal, 2021
Background: Hepatorenal syndrome type II and acute kidney injury found in 20% of cirrhotic patients. Rifaximin was found to reduce the frequency of hepatorenal syndrome type II and acute kidney injury in alcohol cirrhotic patients.
Ahmed El-Gebaly   +2 more
doaj   +1 more source

Dysbiosis in the small intestine: towards an optimal therapy to normalize the gut microbiota [PDF]

open access: yesMicrobiota in Health and Disease, 2021
Objectives: Rifaximin seems to be effective and safe in treating small intestinal bacterial overgrowth (SIBO), however, to date there is no consensus regarding the proper timing of therapy. The present study aims to provide preliminary data regarding the
G. Gasbarrini   +4 more
doaj   +1 more source

Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation [PDF]

open access: yes, 2021
Damage to gut mucosa following conditioning regimens may favour bacterial infections that can trigger graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Rifaximin, an oral and non-absorbable
Ruggeri, Loredana   +16 more
core   +2 more sources

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy

open access: yesFrontiers in Pharmacology, 2021
Objective: Rifaximin has been approved for use as a first-line therapy for secondary prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on efficacy and safety of rifaximin treatment and prevention for HE.Methods: We ...
Xianghui Han   +8 more
doaj   +1 more source

Molecular epidemiology and clinical risk factors for rifaximin-non-susceptible Clostridioides difficile infection in South Korea: a prospective, multicentre, observational study

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: This study was designed to investigate the molecular epidemiology of Clostridioides difficile isolates in South Korea and to evaluate risk factors for rifaximin-non-susceptible C. difficile infection (CDI). Methods: A total of 413 patients
Dokyun Kim   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy